Evidence map›Paper›PMID 27920163›Full record

ArticleJournal of medical ethics2017

Improving on effective antiretroviral therapy: how good will a cure have to be?

Kenneth A Freedberg, Paul E Sax

Abstract readEditorial
In one paragraph

Article in Journal of medical ethics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kenneth A FreedbergMedical Practice Evaluation Center and Divisions of General Internal Medicine and Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Paul E SaxDivision of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Development and application of a new simulation model for COVID-19R01AI042006 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Kenneth Alan Freedberg, Anne Neilan · 1998 to 2026
$12.9M
Novel Methods to Inform HIV/TB Clinical Trial DevelopmentR01AI093269 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI REDDY, KRISHNA P · 2011 to 2024
$6.8M
Novel Methods to Inform HIV/TB Clinical Trial DevelopmentR37AI093269 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALENSKY, ROCHELLE P. · 2015 to 2019
$3.8M
HIV cure studies: risk, risk perception, and ethicsR01AI114617 · NIAID · RUTGERS BIOMEDICAL/HEALTH SCIENCES-RBHS · PI EYAL, NIR · 2015 to 2018
$3.2M
HIV cure studies: risk, risk perception, and ethicsR56AI114617 · NIAID · HARVARD MEDICAL SCHOOL · PI EYAL, NIR · 2014 to 2014
$528k
NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI042006NIAID NIH HHS R01 AI093269NIAID NIH HHS R01 AI114617NIAID NIH HHS R56 AI114617
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antiretroviral Therapy, Highly ActiveAIDS VaccinesBiomedical ResearchCost-Benefit AnalysisDisease EradicationHIV InfectionsHumansPatents as TopicAIDS VaccinesHIV Infection and AIDS

Identifiers

PMID27920163
PMCPMC5269517

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.